---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002550"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:42:14.350557+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q1 ORLADEYO revenue $88.9M (+30% YoY); 2024 guidance raised to $390-$400M

## Summary
- Q1 net loss narrowed to $35.4M ($0.17/sh) from $53.3M ($0.28/sh) a year ago.
- ORLADEYO net revenue grew 30% YoY to $88.9M; full-year guidance raised to $390-$400M (top end of prior range).
- Pipeline: BCX17725 (Netherton syndrome) enters clinic by end 2024; avoralstat (DME) trial planned for 2025.
- Pediatric HAE trial (APeX-P) enrollment complete; filing for label expansion to children age 2+ expected in 2025.
- Cash and investments $338.4M at Mar 31; net cash use Q1 $52.4M, expects ending 2024 cash above $300M.

## SEC filing metadata
- accession: 0001171843-24-002550
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/0001171843-24-002550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/f8k_050624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002550
- JSON: https://secwatch.observer/filing/0001171843-24-002550.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002550.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported the first quarter ended March 31, 2024 results: revenue $92.8 million, net income $35.4 million, EPS $0.17 per share. Guidance raised.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $92.8 million
  - Net income: $35.4 million
  - EPS: $0.17 per share
  - Guidance: raised
  - Result: reported results
  source text: said Dr. Helen Thackray, chief research and development officer of BioCryst. First Quarter 2024 Financial Results For the three months ended March 31, 2024, total revenues were $92.8 million, compared to $68.8 million in the first quarter of 2023 (+34.9 percent y-o-y). The increase was primarily due to $88.9 million in ORLADEYO net revenue in the first quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/0001171843-24-002550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.